CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy. - Myers RM; DiNofia AM; Li Y; Diorio C; Liu H; Wertheim G; Fraietta JA; Gonzalez V; Plesa G; Siegel DL; Iannone E; Shinehouse L; et al. (Journal for immunotherapy of cancer, 2025)